Overview

Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)

Status:
Unknown status

Trial end date:
2021-02-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multicentre, open-label, phase I/II study to evaluate the maximum tolerated dose (MTD), and the most successful dose (MSD) of XOFIGO®, in renal cancer patients with metastases to bone, without (Group A) or with (Group B) visceral metastases.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Treatments:

Radium Ra 223 dichloride
Succinylcholine